1. Home
  2. ARQQ vs OABI Comparison

ARQQ vs OABI Comparison

Compare ARQQ & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arqit Quantum Inc.

ARQQ

Arqit Quantum Inc.

HOLD

Current Price

$23.04

Market Cap

348.7M

Sector

Technology

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

HOLD

Current Price

$4.80

Market Cap

294.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQQ
OABI
Founded
2017
2012
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
348.7M
294.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ARQQ
OABI
Price
$23.04
$4.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
★ $60.00
$4.50
AVG Volume (30 Days)
331.6K
★ 1.4M
Earning Date
05-21-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 6.56
EPS
★ N/A
N/A
Revenue
N/A
★ $18,666,000.00
Revenue This Year
$381.13
$52.42
Revenue Next Year
$212.00
$64.69
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$11.52
$1.32
52 Week High
$62.00
$5.43

Technical Indicators

Market Signals
Indicator
ARQQ
OABI
Relative Strength Index (RSI) 54.66 60.73
Support Level $21.90 $1.90
Resistance Level $24.10 $5.43
Average True Range (ATR) 1.63 0.25
MACD 0.33 -0.02
Stochastic Oscillator 72.24 72.40

Price Performance

Historical Comparison
ARQQ
OABI

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: